GlassScriptPhysician profile
Sandra L Stewart
NPI 1962758862
$2,107.46
in general payments reported to CMS, 2019-2025
12 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2022: $611 · 2023: $414 · 2024: $326 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.67 |
| Education | $152.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $527.86 | 2022-2023 | Imbruvica |
| Incyte Corporation | $248.52 | 2021-2023 | Monjuvi |
| Abbvie INC. | $241.58 | 2021-2024 | |
| Beigene USA, INC. | $239.23 | 2021 | |
| Seagen INC. | $198.97 | 2022 | |
| Astellas Pharma US INC | $152.98 | 2025 | |
| Stemline Therapeutics INC. | $137.67 | 2024 | Orserdu |
| Pharmacosmos Therapeutics INC. | $124.98 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $118.84 | 2023 | Imbruvica |
| Morphosys, US INC. | $70.71 | 2021-2023 | Monjuvi |
| Octapharma USA, INC. | $24.73 | 2024 | Octagam Immune Globulin (Human) |
| Merck Sharp & Dohme LLC | $21.39 | 2024 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.